Clinical Trials Logo

Refractory Leukemia clinical trials

View clinical trials related to Refractory Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04597086 Completed - Acute Leukemia Clinical Trials

Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients

Start date: September 14, 2020
Phase: N/A
Study type: Interventional

This trial investigates how well bright white light therapy works in improving sleep, fatigue, distress, depression, and anxiety, side effects that are often experienced during an intense leukemia treatment regimen, in hospitalized leukemia patients. Bright white light therapy may help to control these symptoms, and information from this study may help doctors and nurses learn more about methods for decreasing these symptoms.

NCT ID: NCT02512926 Completed - Clinical trials for Refractory Solid Tumors

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

POE14-01
Start date: February 16, 2016
Phase: Phase 1
Study type: Interventional

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.

NCT ID: NCT00880269 Completed - Clinical trials for Acute Myelogenous Leukemia

Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Start date: August 2009
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.